Create a company

Creating a spinout company is a popular route for academics who want to be hands-on.

When is a spinout suitable?

You want to remain hands-on

You want to play an active role beyond the research, and gain commercial experience.

There is a clear unmet need and commercial opportunity

If there is a gap in the market and an unmet need for a customer, patient or user, creating a company could be the right way forwards.

You are not prepared to risk significant personal time and effort

This pathway requires a substantial dedication on the researcher's behalf.

You are not comfortable with uncertainty or potential failure

Even with the best idea, planning, and execution, creating a company may not end in success.

1 icon

Identify the potential applications for the research (IP). Assess the market need and the commercial viability. 

2 icon

Identify the founders who wish to play a role in the company, and potential commercial leadership. Begin shaping roles and responsibilities.

3 icon

This stage focuses on market validation and business planning. You will need to spend a lot of time talking to potential customers and others in the industry 'supply chain'.

4 icon

UCL Ventures incorporates the company, while you secure investment, and formalise any governance processes.

5 ICON

UCL Ventures will negotiate fairly with the company on appropriate licensing terms for exclusive access to UCL's IP. This includes (in some cases) royalties, as well as equity.

UCL Ventures will then conclude all contractual arrangements with the company. 

Success stories

Hear the real-world impact that our spinouts have had in the UK and further afield

Trace Neuroscience: slowing motor neurone disease progression with protein restoration
female clinician looking at brain scans

Real-world impact

Trace Neuroscience: slowing motor neurone disease progression with protein restoration

Making progress with restoration of synapse communication with the body.

Gigaton: protecting communities and the climate by cutting industrial emissions
Industrial plant

Real-world impact

Gigaton: protecting communities and the climate by cutting industrial emissions

The founders were concerned about the escalating climate crisis, and frustrated by the lack of global action.

Endomag: reducing breast cancer diagnostic pain and improving access
Endomag Sentimag machine

Real-world impact

Endomag: reducing breast cancer diagnostic pain and improving access

By removing the use of radioactive tracers, more women can access diagnostics.

building icon

The Portico Ventures grants a spinout an exclusive licence to the relevant UCL IP, while UCL Ventures takes a fixed equity stake in the new venture. 

In this model, there are no licensing fees, royalties, or milestone payments - ensuring early capital can be focused on building the business.

Your UCL Ventures Business Manager will confirm if you are eligible for Portico Ventures, based on the the IP position and the proposed business model. 

A licensing ‘heads of terms’ document is then prepared by your Business Manager, setting out the licensing arrangement. This can be shared with potential investors, and will form a core part of the investor’s IP due diligence. 

The full IP licence and equity subscription agreements, based on these heads of terms, are typically executed alongside the first investment round. Bringing licensing and investment together in this way creates a more streamlined process for founders and investors, while helping to reduce legal costs.

magnifying glass icon

Any founding team is eligible for the Portico Ventures model, as long as the IP is owned by UCL; this includes UCL staff, students, or people external to UCL.

calculator icon

This model means UCL Ventures typically takes 5-10% of the spinout’s founding equity. The remaining 90–95% is allocated to the founding team, with at least 10% reserved for an employee option pool to support early hires, advisors and future growth.

UCL Ventures' equity is protected against dilution from the first £1 million of external investment (after which it dilutes as normal).

The equity negotiated will depend on the amount of tailored support provided by the UCL Ventures team during the pathway to market. For researchers who can progress to the first external investment rounds with minimal support, we will typically take a 5% stake.

Common questions

Know your idea could go further?

We can help find the right pathway to market, aligned to your research and your goals.

Speak to the team

Protect your idea

If your idea has potential, the first step is making a disclosure to protect it and explore its commercial future.

Disclose your idea